RU2010130993A - Способы улучшения направленного воздействия на cd138-экспрессирующие опухолевые клетки и агенты для их осуществления - Google Patents
Способы улучшения направленного воздействия на cd138-экспрессирующие опухолевые клетки и агенты для их осуществления Download PDFInfo
- Publication number
- RU2010130993A RU2010130993A RU2010130993/10A RU2010130993A RU2010130993A RU 2010130993 A RU2010130993 A RU 2010130993A RU 2010130993/10 A RU2010130993/10 A RU 2010130993/10A RU 2010130993 A RU2010130993 A RU 2010130993A RU 2010130993 A RU2010130993 A RU 2010130993A
- Authority
- RU
- Russia
- Prior art keywords
- tumor cells
- adhesion
- cytotoxic agent
- immunoconjugate
- inhibits
- Prior art date
Links
- 210000004881 tumor cell Anatomy 0.000 title claims abstract 15
- 229940127089 cytotoxic agent Drugs 0.000 claims abstract 11
- 239000002254 cytotoxic agent Substances 0.000 claims abstract 11
- 231100000599 cytotoxic agent Toxicity 0.000 claims abstract 11
- 229940127121 immunoconjugate Drugs 0.000 claims abstract 10
- 239000012636 effector Substances 0.000 claims abstract 8
- 239000003795 chemical substances by application Substances 0.000 claims abstract 5
- 206010059866 Drug resistance Diseases 0.000 claims abstract 4
- 230000001404 mediated effect Effects 0.000 claims abstract 4
- 210000002536 stromal cell Anatomy 0.000 claims abstract 4
- 210000004027 cell Anatomy 0.000 claims abstract 3
- JSHOVKSMJRQOGY-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(pyridin-2-yldisulfanyl)butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCSSC1=CC=CC=N1 JSHOVKSMJRQOGY-UHFFFAOYSA-N 0.000 claims abstract 2
- 230000004565 tumor cell growth Effects 0.000 claims abstract 2
- 230000004614 tumor growth Effects 0.000 claims abstract 2
- 230000003313 weakening effect Effects 0.000 claims abstract 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 2
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 229940123237 Taxane Drugs 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims 1
- 229960001467 bortezomib Drugs 0.000 claims 1
- 201000008275 breast carcinoma Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 229960000684 cytarabine Drugs 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- 229960003957 dexamethasone Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 1
- 229960005420 etoposide Drugs 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 201000007487 gallbladder carcinoma Diseases 0.000 claims 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 1
- 229960004942 lenalidomide Drugs 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- -1 prendisone Chemical compound 0.000 claims 1
- 201000010174 renal carcinoma Diseases 0.000 claims 1
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 claims 1
- 229960003452 romidepsin Drugs 0.000 claims 1
- OHRURASPPZQGQM-UHFFFAOYSA-N romidepsin Natural products O1C(=O)C(C(C)C)NC(=O)C(=CC)NC(=O)C2CSSCCC=CC1CC(=O)NC(C(C)C)C(=O)N2 OHRURASPPZQGQM-UHFFFAOYSA-N 0.000 claims 1
- 108010091666 romidepsin Proteins 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 229960003787 sorafenib Drugs 0.000 claims 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 1
- 229960003433 thalidomide Drugs 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 1
- 229960004528 vincristine Drugs 0.000 claims 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
1. Способ уменьшения адгезии стромальных клеток к CD138-экспрессирующим опухолевым клеткам в опухолевых клетках нуждающегося субъекта, который включает: ! введение в указанные опухолевые клетки иммуноконъюгата против CD138-экспрессирующих опухолевых клеток в количестве, эффективном для уменьшения адгезии стромальных клеток к CD138-экспрессирующим опухолевым клеткам, и, необязательно, введение в указанные опухолевые клетки дополнительного цитотоксического средства в количестве, ингибирующем, задерживающем и/или предотвращающем рост опухолевых клеток. ! 2. Способ по п.1, в котором указанный иммуноконъюгат включает эффекторную молекулу и агент против клетки-мишени, причем указанная эффекторная молекула и указанный агент против клетки-мишени связаны друг с другом при помощи расщепляемого линкера. ! 3. Способ по п.2, в котором расщепляемый линкер содержит дисульфидную связь. ! 4. Способ по п.3, в котором линкер является SPP или SPDB. ! 5. Способ по любому из пп.1-4, в котором адгезия уменьшена, по меньшей мере, примерно на 10%, примерно на 20%, примерно на 30%, примерно на 40%, примерно на 50%, примерно на 60%, примерно на 70%, примерно на 80% или больше. ! 6. Способ по любому из пп.1-4, в котором указанная уменьшенная адгезия вызывает ослабление опосредуемой адгезией устойчивости к лекарствам. ! 7. Способ по п.6, в котором уменьшена опосредуемая адгезией устойчивость к лекарствам в отношении дополнительного цитотоксического средства, не являющегося указанным иммуноконъюгатом, и в котором указанное дополнительное цитотоксическое средство вводят в количестве, ингибирующем, задерживающем и/или предотвращающем рост опухолевых клеток. ! 8. Способ по
Claims (18)
1. Способ уменьшения адгезии стромальных клеток к CD138-экспрессирующим опухолевым клеткам в опухолевых клетках нуждающегося субъекта, который включает:
введение в указанные опухолевые клетки иммуноконъюгата против CD138-экспрессирующих опухолевых клеток в количестве, эффективном для уменьшения адгезии стромальных клеток к CD138-экспрессирующим опухолевым клеткам, и, необязательно, введение в указанные опухолевые клетки дополнительного цитотоксического средства в количестве, ингибирующем, задерживающем и/или предотвращающем рост опухолевых клеток.
2. Способ по п.1, в котором указанный иммуноконъюгат включает эффекторную молекулу и агент против клетки-мишени, причем указанная эффекторная молекула и указанный агент против клетки-мишени связаны друг с другом при помощи расщепляемого линкера.
3. Способ по п.2, в котором расщепляемый линкер содержит дисульфидную связь.
4. Способ по п.3, в котором линкер является SPP или SPDB.
5. Способ по любому из пп.1-4, в котором адгезия уменьшена, по меньшей мере, примерно на 10%, примерно на 20%, примерно на 30%, примерно на 40%, примерно на 50%, примерно на 60%, примерно на 70%, примерно на 80% или больше.
6. Способ по любому из пп.1-4, в котором указанная уменьшенная адгезия вызывает ослабление опосредуемой адгезией устойчивости к лекарствам.
7. Способ по п.6, в котором уменьшена опосредуемая адгезией устойчивость к лекарствам в отношении дополнительного цитотоксического средства, не являющегося указанным иммуноконъюгатом, и в котором указанное дополнительное цитотоксическое средство вводят в количестве, ингибирующем, задерживающем и/или предотвращающем рост опухолевых клеток.
8. Способ по п.7, в котором указанное цитотоксическое средство представляет собой мефалан, винкристин, доксорубицин, дексаметазон, циклофосфамид, этопозид, цитарабин, цисплатин, талидомид, прендизон, бортезомиб, леналидомид, сорафениб, ромидепсин или их комбинации.
9. Способ по п.7, в котором цитотоксическое средство создано на основе антитела.
10. Способ по п.1 или 2, в котором указанная эффекторная молекула имеет стерическое препятствие.
11. Способ по п.1 или 2, в котором эффекторная молекула представляет собой, по меньшей мере, один майтанзиноид, таксан, СС1065 или их аналог.
12. Способ по п.11, в котором эффекторная молекула представляет собой, по меньшей мере, один майтанзиноид, такой как DM1, DM3 или DM4.
13. Способ по п.12, в котором указанная эффекторная молекула представляет собой DM4.
14. Способ по любому из пп.1-4, в котором указанный агент против клетки-мишени иммуноконъюгата включает:
аминокислотную последовательность тяжелой цепи иммуноглобулина или ее части, где указанная тяжелая цепь иммуноглобулина или ее части, по меньшей мере, на 70%, по меньшей мере, на 80%, по меньшей мере, на 90%, по меньшей мере, на 85% или, по меньшей мере, на 98% идентичны SEQ ID NO:1.
15. Способ по п.7, в котором иммуноконъюгат и цитотоксическое средство вводят последовательно, где цитотоксическое средство вводят после введения иммуноконъюгата.
16. Способ по п.7, в котором иммуноконъюгат и цитотоксическое средство вводят одновременно.
17. Способ по любому из пп.1-4 и 7-9, в котором указанный субъект является раковым пациентом, страдающим одним из следующих заболеваний: множественная миелома, карцинома яичника, карцинома почки, карцинома желчного пузыря, карцинома молочной железы, рак предстательной железы, рак легкого, карцинома толстой кишки, лимфома Ходжкина и неходжкинская лимфома, хронический лимфолейкоз (CLL), острый лимфобластный лейкоз (ALL), острый миелобластный лейкоз (AML) и солидная тканевая саркома.
18. Способ по п.17, в котором указанный пациент страдает множественной миеломой.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1661407P | 2007-12-26 | 2007-12-26 | |
US61/016,614 | 2007-12-26 | ||
US8759008P | 2008-08-08 | 2008-08-08 | |
US8746608P | 2008-08-08 | 2008-08-08 | |
US61/087,466 | 2008-08-08 | ||
US61/087,590 | 2008-08-08 | ||
PCT/EP2008/068270 WO2009080832A1 (en) | 2007-12-26 | 2008-12-23 | Methods and agents for improving targeting of cd138 expressing tumor cells |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2010130993A true RU2010130993A (ru) | 2012-02-10 |
RU2486203C2 RU2486203C2 (ru) | 2013-06-27 |
Family
ID=40481710
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2010130993/10A RU2486203C2 (ru) | 2007-12-26 | 2008-12-23 | Способы улучшения направленного воздействия на cd138-экспрессирующие опухолевые клетки и агенты для их осуществления |
Country Status (18)
Country | Link |
---|---|
US (1) | US9446146B2 (ru) |
EP (1) | EP2240516B1 (ru) |
JP (2) | JP2011508738A (ru) |
KR (1) | KR101579218B1 (ru) |
CN (1) | CN101945892B (ru) |
AR (1) | AR069978A1 (ru) |
AU (1) | AU2008339913B2 (ru) |
BR (1) | BRPI0821417A2 (ru) |
CA (1) | CA2710483C (ru) |
ES (1) | ES2543201T3 (ru) |
HK (1) | HK1149032A1 (ru) |
IL (1) | IL206552A (ru) |
MX (1) | MX2010007101A (ru) |
PL (1) | PL2240516T3 (ru) |
RU (1) | RU2486203C2 (ru) |
TW (1) | TWI450726B (ru) |
WO (1) | WO2009080832A1 (ru) |
ZA (1) | ZA201004326B (ru) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9221914B2 (en) | 2007-12-26 | 2015-12-29 | Biotest Ag | Agents targeting CD138 and uses thereof |
US9387261B2 (en) | 2007-12-26 | 2016-07-12 | Biotest Ag | Immunoconjugates targeting CD138 and uses thereof |
US9446146B2 (en) | 2007-12-26 | 2016-09-20 | Biotest Ag | Methods and agents for improving targeting of CD138 expressing tumor cells |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060045877A1 (en) * | 2004-08-30 | 2006-03-02 | Goldmakher Viktor S | Immunoconjugates targeting syndecan-1 expressing cells and use thereof |
AU2013201618B2 (en) * | 2009-05-06 | 2016-06-02 | Biotest Ag | Uses of immunoconjugates targeting CD138 |
KR101725170B1 (ko) * | 2009-05-06 | 2017-04-10 | 바이오테스트 아게 | Cd138을 표적으로 하는 면역접합체의 용도 |
CA2793838C (en) | 2010-03-19 | 2019-09-17 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | Integrin interaction inhibitors for the treatment of cancer |
KR102037541B1 (ko) | 2011-10-28 | 2019-10-29 | 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 | 폴리펩티드 구축물 및 이의 용도 |
RU2632108C2 (ru) | 2011-12-08 | 2017-10-02 | Биотест Аг | Применения иммуноконъюгатов, мишенью которых является cd138 |
US20150037358A1 (en) * | 2012-03-09 | 2015-02-05 | Lankenau Institute For Medical Research | Composition and Methods for Treating Cancer |
CN112587658A (zh) * | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
US9353150B2 (en) | 2012-12-04 | 2016-05-31 | Massachusetts Institute Of Technology | Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment |
WO2014089354A1 (en) * | 2012-12-07 | 2014-06-12 | The Regents Of The University Of California | Cd138-targeted interferon demonstrates potent apoptotic and anti-tumor activities |
US10093745B2 (en) | 2013-05-29 | 2018-10-09 | The Regents Of The University Of California | Anti-CSPG4 fusions with interferon for the treatment of malignancy |
US10011635B2 (en) | 2013-09-27 | 2018-07-03 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Cyclic peptide conjugates and methods of use |
ES2785551T3 (es) | 2014-06-30 | 2020-10-07 | Glykos Finland Oy | Derivado de sacárido de una carga útil tóxica y sus conjugados con anticuerpos |
RU2611685C2 (ru) * | 2015-07-20 | 2017-02-28 | Илья Владимирович Духовлинов | Гуманизированное моноклональное антитело, специфичное к синдекану-1 |
WO2017197045A1 (en) | 2016-05-11 | 2017-11-16 | Movassaghi Mohammad | Convergent and enantioselective total synthesis of communesin analogs |
US11242403B2 (en) * | 2017-04-26 | 2022-02-08 | Mitsubishi Tanabe Pharma Corporation | Syndecan-1 (CD138) binding agents and uses thereof |
US11932650B2 (en) | 2017-05-11 | 2024-03-19 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
US11945868B2 (en) * | 2017-10-02 | 2024-04-02 | Visterra, Inc. | Antibody molecules to CD138 and uses thereof |
US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
CA3133155A1 (en) | 2019-03-19 | 2020-09-24 | Fundacio Privada Institut D'investigacio Oncologica De Vall Hebron | Combination therapy for the treatment for cancer |
JP7412440B2 (ja) | 2019-03-29 | 2024-01-12 | エフ. ホフマン-ラ ロシュ アーゲー | アビド結合多重特異性抗体を作製する方法 |
WO2020247054A1 (en) | 2019-06-05 | 2020-12-10 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
WO2024089013A1 (en) | 2022-10-25 | 2024-05-02 | Peptomyc, S.L. | Combination therapy for the treatment of cancer |
Family Cites Families (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3896111A (en) | 1973-02-20 | 1975-07-22 | Research Corp | Ansa macrolides |
US4151042A (en) | 1977-03-31 | 1979-04-24 | Takeda Chemical Industries, Ltd. | Method for producing maytansinol and its derivatives |
US4169888A (en) | 1977-10-17 | 1979-10-02 | The Upjohn Company | Composition of matter and process |
US4137230A (en) | 1977-11-14 | 1979-01-30 | Takeda Chemical Industries, Ltd. | Method for the production of maytansinoids |
US4265814A (en) | 1978-03-24 | 1981-05-05 | Takeda Chemical Industries | Matansinol 3-n-hexadecanoate |
US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
JPS5562090A (en) | 1978-10-27 | 1980-05-10 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS5566585A (en) | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS55164687A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
JPS55164685A (en) | 1979-06-08 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS55164686A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
US4309428A (en) | 1979-07-30 | 1982-01-05 | Takeda Chemical Industries, Ltd. | Maytansinoids |
JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
US4761111A (en) | 1981-09-18 | 1988-08-02 | Brown Andrew M | Automobile lifting and towing equipment |
US4418064A (en) | 1982-09-29 | 1983-11-29 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids: treflorine, trenudine, and N-methyltrenudone |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
CA1340312C (en) | 1986-10-09 | 1999-01-12 | Paul G. Abrams | Methods for improved targeting of antibody, antibody fragments, hormonesand other targeting agents and conjugates thereof |
US5053394A (en) | 1988-09-21 | 1991-10-01 | American Cyanamid Company | Targeted forms of methyltrithio antitumor agents |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
WO1991010741A1 (en) | 1990-01-12 | 1991-07-25 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
EP0527189A1 (en) | 1990-04-25 | 1993-02-17 | PHARMACIA & UPJOHN COMPANY | Novel cc-1065 analogs |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
US5998656A (en) | 1991-09-23 | 1999-12-07 | Florida State University | C10 tricyclic taxanes |
US6080777A (en) | 1992-01-31 | 2000-06-27 | The Trustees Of Columbia University In The City Of New York | Taxol as a radiation sensitizer |
US5200534A (en) | 1992-03-13 | 1993-04-06 | University Of Florida | Process for the preparation of taxol and 10-deacetyltaxol |
CA2076465C (en) | 1992-03-25 | 2002-11-26 | Ravi V. J. Chari | Cell binding agent conjugates of analogues and derivatives of cc-1065 |
US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
US5703247A (en) | 1993-03-11 | 1997-12-30 | Virginia Tech Intellectual Properties, Inc. | 2-Debenzoyl-2-acyl taxol derivatives and methods for making same |
US5475011A (en) | 1993-03-26 | 1995-12-12 | The Research Foundation Of State University Of New York | Anti-tumor compounds, pharmaceutical compositions, methods for preparation thereof and for treatment |
US6740734B1 (en) | 1994-01-14 | 2004-05-25 | Biovitrum Ab | Bacterial receptor structures |
SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
US5763477A (en) | 1994-07-22 | 1998-06-09 | Dr. Reddy's Research Foundation | Taxane derivatives from 14-β-hydroxy-10 deacetylbaccatin III |
JPH11501931A (ja) | 1995-03-10 | 1999-02-16 | ハウザー,インコーポレイテッド | セファロマンニンエポキシド、その類似体およびそれらの製造方法 |
CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
PT923941E (pt) * | 1996-06-27 | 2006-09-29 | Chugai Pharmaceutical Co Ltd | Medicamentos para mieloma a serem utilizados com agentes antitumorais de mostarda nitrogenada |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
CN100387621C (zh) | 1997-04-14 | 2008-05-14 | 麦可麦脱股份公司 | 抗人抗原受体的新的生产方法及其用途 |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
US6962702B2 (en) | 1998-06-22 | 2005-11-08 | Immunomedics Inc. | Production and use of novel peptide-based agents for use with bi-specific antibodies |
US6087362A (en) | 1999-03-16 | 2000-07-11 | Pentech Pharmaceuticals, Inc. | Apomorphine and sildenafil composition |
ATE349438T1 (de) | 1999-11-24 | 2007-01-15 | Immunogen Inc | Cytotoxische wirkstoffe enthaltend taxane und deren therapeutische anwendung |
US20030203451A1 (en) | 2000-08-24 | 2003-10-30 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
US6333410B1 (en) | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
DE60136281D1 (de) | 2000-08-24 | 2008-12-04 | Genentech Inc | Methode zur inhibierung von il-22 induziertem pap1 |
CA2420193A1 (en) | 2000-08-24 | 2002-02-28 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
CN1555411A (zh) * | 2001-08-03 | 2004-12-15 | ���迨�����\���ɷݹ�˾ | 抗体-依赖性细胞毒性增大的抗体糖基化变体 |
US6716821B2 (en) | 2001-12-21 | 2004-04-06 | Immunogen Inc. | Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same |
US6756397B2 (en) | 2002-04-05 | 2004-06-29 | Immunogen, Inc. | Prodrugs of CC-1065 analogs |
US6534660B1 (en) | 2002-04-05 | 2003-03-18 | Immunogen, Inc. | CC-1065 analog synthesis |
LT1507556T (lt) | 2002-05-02 | 2016-10-10 | Wyeth Holdings Llc | Kalicheamicino darinio ir nešiklio konjugatai |
US20050276812A1 (en) | 2004-06-01 | 2005-12-15 | Genentech, Inc. | Antibody-drug conjugates and methods |
US6596757B1 (en) | 2002-05-14 | 2003-07-22 | Immunogen Inc. | Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use |
US7390898B2 (en) | 2002-08-02 | 2008-06-24 | Immunogen Inc. | Cytotoxic agents containing novel potent taxanes and their therapeutic use |
US20040126379A1 (en) | 2002-08-21 | 2004-07-01 | Boehringer Ingelheim International Gmbh | Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents |
US7534427B2 (en) * | 2002-12-31 | 2009-05-19 | Immunomedics, Inc. | Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins |
NZ541503A (en) | 2003-01-22 | 2008-09-26 | Glycart Biotechnology Ag | Fusion constructs and use of same to produce antibodies with increased Fc receptor binding affinity and effector function |
US7449303B2 (en) * | 2003-05-02 | 2008-11-11 | Health Research, Inc. | Use of JAG2 expression in diagnosis of plasma cell disorders |
US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
ME00425B (me) * | 2003-05-30 | 2011-10-10 | Genentech Inc | Liječenje sa anti-vegf antitijelima |
WO2005009369A2 (en) | 2003-07-21 | 2005-02-03 | Immunogen, Inc. | A ca6 antigen-specific cytotoxic conjugate and methods of using the same |
US7271245B2 (en) | 2004-02-13 | 2007-09-18 | The Scripps Research Institute | Methods and compositions for inhibition of metastasis |
SI2311874T1 (sl) | 2004-07-22 | 2017-12-29 | Erasmus University Medical Center Rotterdam Department of Cell Biology and Genetics | Vezavne molekule |
US20060045877A1 (en) * | 2004-08-30 | 2006-03-02 | Goldmakher Viktor S | Immunoconjugates targeting syndecan-1 expressing cells and use thereof |
SG10201912554TA (en) | 2005-03-23 | 2020-02-27 | Genmab As | Antibodies against cd38 for treatment of multiple myeloma |
WO2006110466A2 (en) | 2005-04-07 | 2006-10-19 | Novartis Vaccines And Diagnostics Inc. | CANCER-RELATED GENES (PTPϵ) |
EP1868649A4 (en) | 2005-04-15 | 2011-06-29 | Immunogen Inc | ELIMINATION OF A POPULATION OF HETEROGENEOUS OR MIXED CELLS IN TUMORS |
BRPI0619460A2 (pt) | 2005-12-06 | 2011-11-08 | Domantis Ltd | ligando, uso do ligando, composição, dispositivo de dispensação de medicamento, ácido nucléico isolado ou recombinante, vetor, célula hospedeira, e, método para produzir um ligando |
EA200802061A1 (ru) * | 2006-03-28 | 2009-04-28 | Байоджен Айдек Эмэй Инк. | Антитело или его фрагмент, специфично связывающееся с рецептором 1 инсулиноподобного фактора роста (igf-r1) (варианты), композиция на его основе, полинуклеотид, кодирующий вариабельную область антитела (варианты), содержащие полинуклеотид композиция (варианты) и вектор, содержащая вектор клетка-хозяин (варианты), способ продуцирования антитела или его фрагмента (варианты) и способ лечения гиперпролиферативного заболевания у животного организма |
ES2568436T3 (es) | 2006-03-31 | 2016-04-29 | Chugai Seiyaku Kabushiki Kaisha | Procedimiento para controlar la farmacocinética en sangre de anticuerpos |
US20100291105A1 (en) | 2006-05-03 | 2010-11-18 | Elke Pogge Von Strandmann | Agent for the treatment of malignant diseases |
CN102133048B (zh) | 2007-10-04 | 2014-04-30 | 雀巢产品技术援助有限公司 | 用于饮料制备设备的集成的加热器 |
EP2238169A1 (en) | 2007-12-26 | 2010-10-13 | Biotest AG | Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates |
DK2242772T3 (en) | 2007-12-26 | 2015-01-05 | Biotest Ag | Immunoconjugates that targets CD138, and uses thereof |
CA2710483C (en) | 2007-12-26 | 2018-05-08 | Biotest Ag | Methods and agents for improving targeting of cd138 expressing tumor cells |
CN101952315B (zh) | 2007-12-26 | 2015-04-01 | 生物测试股份公司 | 靶向cd138的试剂及其应用 |
KR101725170B1 (ko) | 2009-05-06 | 2017-04-10 | 바이오테스트 아게 | Cd138을 표적으로 하는 면역접합체의 용도 |
-
2008
- 2008-12-23 CA CA2710483A patent/CA2710483C/en not_active Expired - Fee Related
- 2008-12-23 US US12/342,815 patent/US9446146B2/en not_active Expired - Fee Related
- 2008-12-23 RU RU2010130993/10A patent/RU2486203C2/ru not_active IP Right Cessation
- 2008-12-23 ES ES08865592.3T patent/ES2543201T3/es active Active
- 2008-12-23 MX MX2010007101A patent/MX2010007101A/es active IP Right Grant
- 2008-12-23 AU AU2008339913A patent/AU2008339913B2/en not_active Ceased
- 2008-12-23 WO PCT/EP2008/068270 patent/WO2009080832A1/en active Application Filing
- 2008-12-23 JP JP2010540132A patent/JP2011508738A/ja active Pending
- 2008-12-23 EP EP08865592.3A patent/EP2240516B1/en not_active Not-in-force
- 2008-12-23 BR BRPI0821417-4A patent/BRPI0821417A2/pt not_active Application Discontinuation
- 2008-12-23 CN CN200880126958.8A patent/CN101945892B/zh not_active Expired - Fee Related
- 2008-12-23 KR KR1020107016664A patent/KR101579218B1/ko active IP Right Grant
- 2008-12-23 AR ARP080105721A patent/AR069978A1/es unknown
- 2008-12-23 PL PL08865592T patent/PL2240516T3/pl unknown
- 2008-12-24 TW TW097150431A patent/TWI450726B/zh not_active IP Right Cessation
-
2010
- 2010-06-18 ZA ZA2010/04326A patent/ZA201004326B/en unknown
- 2010-06-22 IL IL206552A patent/IL206552A/en active IP Right Grant
-
2011
- 2011-03-31 HK HK11103272.0A patent/HK1149032A1/xx not_active IP Right Cessation
-
2015
- 2015-03-04 JP JP2015042307A patent/JP2015127331A/ja active Pending
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9221914B2 (en) | 2007-12-26 | 2015-12-29 | Biotest Ag | Agents targeting CD138 and uses thereof |
US9387261B2 (en) | 2007-12-26 | 2016-07-12 | Biotest Ag | Immunoconjugates targeting CD138 and uses thereof |
US9446146B2 (en) | 2007-12-26 | 2016-09-20 | Biotest Ag | Methods and agents for improving targeting of CD138 expressing tumor cells |
Also Published As
Publication number | Publication date |
---|---|
PL2240516T3 (pl) | 2015-12-31 |
CN101945892A (zh) | 2011-01-12 |
KR101579218B1 (ko) | 2015-12-21 |
US9446146B2 (en) | 2016-09-20 |
AU2008339913B2 (en) | 2014-03-20 |
WO2009080832A1 (en) | 2009-07-02 |
ZA201004326B (en) | 2011-04-28 |
TWI450726B (zh) | 2014-09-01 |
CA2710483A1 (en) | 2009-07-02 |
ES2543201T3 (es) | 2015-08-17 |
IL206552A (en) | 2016-04-21 |
AU2008339913A1 (en) | 2009-07-02 |
US20090169570A1 (en) | 2009-07-02 |
HK1149032A1 (en) | 2011-09-23 |
AR069978A1 (es) | 2010-03-03 |
EP2240516A1 (en) | 2010-10-20 |
CA2710483C (en) | 2018-05-08 |
JP2015127331A (ja) | 2015-07-09 |
IL206552A0 (en) | 2010-12-30 |
RU2486203C2 (ru) | 2013-06-27 |
KR20100098717A (ko) | 2010-09-08 |
CN101945892B (zh) | 2017-11-24 |
BRPI0821417A2 (pt) | 2015-06-16 |
EP2240516B1 (en) | 2015-07-08 |
MX2010007101A (es) | 2011-07-01 |
TW200936163A (en) | 2009-09-01 |
JP2011508738A (ja) | 2011-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2010130993A (ru) | Способы улучшения направленного воздействия на cd138-экспрессирующие опухолевые клетки и агенты для их осуществления | |
JP2011508738A5 (ru) | ||
RU2010130977A (ru) | Иммуноконъюгаты, направленные на cd138, и их применение | |
US20200289661A1 (en) | Cd48 antibodies and conjugates thereof | |
JP2019532056A5 (ru) | ||
JP2020525542A5 (ru) | ||
JP2011507932A5 (ru) | ||
JP2012522513A5 (ru) | ||
JP2017110002A5 (ru) | ||
FI3316909T3 (fi) | NTB-A-vasta-aineita ja liittyviä koostumuksia ja menetelmiä | |
RU2016117810A (ru) | Конъюгаты белок-полимер-лекарственное средство | |
JP2016523810A5 (ru) | ||
RU2019142720A (ru) | Способ двойной конъюгации для получения конъюгатов антитело-лекарственное средство | |
JP2014522850A5 (ru) | ||
JP2008537673A5 (ru) | ||
JP2008515889A5 (ru) | ||
JP2020526584A5 (ru) | ||
JP2020511481A5 (ru) | ||
WO2021142043A1 (en) | Anti-slc34a2 antibodies, antibody drug conjugates, and methods of use thereof | |
RU2019129839A (ru) | Производные майтанзиноида с саморасщепляющимися пептидными линкерами и их конъюгаты | |
MX2021010003A (es) | Anticuerpos anti-mertk de alta afinidad y usos de los mismos. | |
JP2016532688A5 (ru) | ||
JP2021500055A5 (ru) | ||
US20190290775A1 (en) | Use of Antibody Drug Conjugates Comprising Tubulin Disrupting Agents to Treat Solid Tumor | |
M Gromek et al. | Natural products as exquisitely potent cytotoxic payloads for antibody-drug conjugates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
TC4A | Change in inventorship |
Effective date: 20160915 |
|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20191224 |